Intech Investment Management LLC Increases Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Intech Investment Management LLC lifted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 224.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 42,156 shares of the company's stock after acquiring an additional 29,167 shares during the period. Intech Investment Management LLC owned 0.09% of Amphastar Pharmaceuticals worth $1,565,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in AMPH. GSA Capital Partners LLP acquired a new stake in Amphastar Pharmaceuticals during the third quarter worth approximately $303,000. Quest Partners LLC raised its stake in Amphastar Pharmaceuticals by 74.4% during the 3rd quarter. Quest Partners LLC now owns 7,586 shares of the company's stock worth $368,000 after acquiring an additional 3,237 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new stake in Amphastar Pharmaceuticals in the third quarter valued at $921,000. Algert Global LLC acquired a new position in Amphastar Pharmaceuticals in the third quarter valued at $3,217,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of Amphastar Pharmaceuticals by 59.6% during the third quarter. BNP Paribas Financial Markets now owns 94,466 shares of the company's stock worth $4,584,000 after purchasing an additional 35,284 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Piper Sandler decreased their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research report on Friday, March 21st.

Remove Ads

Amphastar Pharmaceuticals Stock Performance

AMPH stock traded down $0.02 on Wednesday, hitting $28.37. The company's stock had a trading volume of 437,895 shares, compared to its average volume of 428,739. Amphastar Pharmaceuticals, Inc. has a 1 year low of $25.89 and a 1 year high of $53.96. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of 9.46, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77. The firm has a 50 day moving average of $31.52 and a two-hundred day moving average of $40.24.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the sale, the chief financial officer now directly owns 97,363 shares of the company's stock, valued at $2,681,377.02. This represents a 4.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 27.10% of the company's stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.